{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:49:57Z","timestamp":1777085397809,"version":"3.51.4"},"reference-count":46,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science Committee of RA","award":["20TTWS-1D009"],"award-info":[{"award-number":["20TTWS-1D009"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Background: Neurotic disturbances, anxiety, neurosis-like disorders, and stress situations are widespread. Benzodiazepine tranquillizers have been found to be among the most effective antianxiety drugs. The pharmacological action of benzodiazepines is due to their interaction with the supra-molecular membrane GABA-a-benzodiazepine receptor complex, linked to the Cl-ionophore. Benzodiazepines enhance GABA-ergic transmission and this has led to a study of the role of GABA in anxiety. The search for anxiolytics and anticonvulsive agents has involved glutamate-ergic, 5HT-ergic substances and neuropeptides. However, each of these well-known anxiolytics, anticonvulsants and cognition enhancers (nootropics) has repeatedly been reported to have many adverse side effects, therefore there is an urgent need to search for new drugs able to restore damaged cognitive functions without causing significant adverse reactions. Objective: Considering the relevance of epilepsy diffusion in the world, we have addressed our attention to the discovery of new drugs in this field Thus our aim is the synthesis and study of new compounds with antiepileptic (anticonvulsant) and not only, activity. Methods: For the synthesis of compounds classical organic methods were used and developed. For the evaluation of biological activity some anticonvulsant and psychotropic methods were used. Results: As a result of multistep reactions 26 new, five-membered heterocyclic systems were obtained. PASS prediction of anticonvulsant activity was performed for the whole set of the designed molecules and probability to be active Pa values were ranging from 0.275 to 0.43. The studied compounds exhibit protection against pentylenetetrazole (PTZ) seizures, anti-thiosemicarbazides effect as well as some psychotropic effect. The biological assays evidenced that some of the studied compounds showed a high anticonvulsant activity by antagonism with pentylenetetrazole. The toxicity of compounds is low and they do not induce muscle relaxation in the studied doses. According to the study of psychotropic activity it was found that the selected compounds have an activating behavior and anxiolytic effects on the models of \u201copen field\u201d and \u201celevated plus maze\u201d (EPM). The data obtained indicate the anxiolytic (anti-anxiety) activity of the derivatives of pyrimidines, especially pronounced in compounds 6n, 6b, and 7c. The studied compounds increase the latent time of first immobilization on the model of \u201cforced swimming\u201d (FST) and exhibit some antidepressant effect similarly to diazepam. Docking studies revealed that compound 6k bound tightly in the active site of GABAA receptor with a value of the scoring function that estimates free energy of binding (\u0394G) at \u22127.95 kcal\/mol, while compound 6n showed the best docking score and seems to be dual inhibitor of SERT transporter as well as 5-HT1A receptor. Conclusions: \u0422he selected compounds have an anticonvulsant, activating behavior and anxiolytic effects, at the same time exhibit some antidepressant effect.<\/jats:p>","DOI":"10.3390\/molecules26113320","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T15:58:44Z","timestamp":1622563124000},"page":"3320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Synthesis and Neurotropic Activity of New Heterocyclic Systems: Pyridofuro[3,2-d]pyrrolo[1,2-a]pyrimidines, Pyridofuro[3,2-d]pyrido[1,2-a]pyrimidines and Pyridofuro[3\u2032,2\u2032:4,5]pyrimido[1,2-a]azepines"],"prefix":"10.3390","volume":"26","author":[{"given":"Samvel N.","family":"Sirakanyan","sequence":"first","affiliation":[{"name":"Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica G. Ciamician, Alma Mater Studiorum-Universit\u00e0 di Bologna, Via F. Selmi 2, 40126 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9894-7777","authenticated-orcid":false,"given":"Athina","family":"Geronikaki","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Kartsev","sequence":"additional","affiliation":[{"name":"InterBioScreen, a\/ya 218, 119019 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmira K.","family":"Hakobyan","sequence":"additional","affiliation":[{"name":"Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8587-2710","authenticated-orcid":false,"given":"Anthi","family":"Petrou","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruzanna G.","family":"Paronikyan","sequence":"additional","affiliation":[{"name":"Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivetta M.","family":"Nazaryan","sequence":"additional","affiliation":[{"name":"Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasmik H.","family":"Akopyan","sequence":"additional","affiliation":[{"name":"Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anush A.","family":"Hovakimyan","sequence":"additional","affiliation":[{"name":"Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF02539219","article-title":"Synthesis and anticonvulsive activity of a series of new pyrano(thiopyrano,pyrido)[4\u2032,3\u2032:4,5]thieno[2,3-d]pyrimidines","volume":"32","author":"Mkrtchyan","year":"1998","journal-title":"Pharm. Chem. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF00772002","article-title":"Synthesis and antitubercular activity of benzothieno[2,3-d]pyrimidines","volume":"25","author":"Kapustina","year":"1991","journal-title":"Pharm. Chem. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/jm00392a003","article-title":"Nitrogen bridgehead compounds. 66. Bronchodilator nitrogen bridgehead compounds with a pyrimidinone moiety","volume":"30","author":"Hermecz","year":"1987","journal-title":"J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8379","DOI":"10.1016\/j.tetlet.2007.09.072","article-title":"Synthesis of a hexahydropyrimido[1,2-a]azepine-2-carboxamide derivative useful as an HIV integrase inhibitor","volume":"48","author":"Ferrara","year":"2007","journal-title":"Tetrahedron Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1021\/ol802604v","article-title":"Catalytic Asymmetric Synthesis of an HIV Integrase Inhibitor","volume":"11","author":"Zhong","year":"2009","journal-title":"Org. Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49028","DOI":"10.1039\/C6RA06507D","article-title":"Pyridofuropyrrolo[1,2-a]pyrimidines and pyridofuropyrimido[1,2-a]azepines: New chemical entities (NCE) with anticonvulsive and psychotropic properties","volume":"6","author":"Sirakanyan","year":"2016","journal-title":"RSC Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/jm00258a008","article-title":"Pyrimido[4,5-c]isoquinolines. 2. Synthesis and biological evaluation of some 6-alkyl-, 6-aralkyl-, and 6-aryl-1,3-diamino-7,8,9,10-tetrahydropyrimido[4,5-c]isoquinolines as potential folate antagonists","volume":"17","author":"Rosowsky","year":"1974","journal-title":"J. Med. Chem."},{"key":"ref_8","unstructured":"Kartsev, V.G., and Tolstikov, G.A. (2001). The Chemistry and Biological Activity of Nitrogen-Containing Heterocycles and Alkaloids, Iridium Press. Available online: http:\/\/cbcconf.com\/izd\/azot-e.htm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/BF00479620","article-title":"Synthesis and structure of 3-oxopyrano[3,4-c]pyridines","volume":"25","author":"Paronikyan","year":"1989","journal-title":"Chem. Heterocycl. Compd."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10637","DOI":"10.1016\/j.tet.2013.10.015","article-title":"Synthesis and structure of condensed triazolo- and tetrazolopyrimidines","volume":"69","author":"Sirakanyan","year":"2013","journal-title":"Tetrahedron"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1016\/j.tet.2015.03.114","article-title":"On the reaction of 2-[(4-cyano-5,6,7,8-tetrahydroisoquinolin-3-yl)oxy]acetamides with bases: 1-amino-6,7,8,9-tetrahydrofuro[2,3-c]isoquinoline-2-carboxamides and 3-amino-4-cyano-5,6,7,8-tetrahydroisoquinolines via a Smiles-type rearrangement","volume":"71","author":"Sirakanyan","year":"2015","journal-title":"Tetrahedron"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/jhet.2693","article-title":"New Methods for the Synthesis of 3-Amino-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitriles and Cyclopenta[d]pyrazolo[3,4-b]-pyridines via a Smiles-type Rearrangement","volume":"54","author":"Sirakanyan","year":"2017","journal-title":"J. Heterocycl. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1134\/S1070428020100310","article-title":"Synthesis and Transformations of Oxy Amides Derived from Cycloalka[c]- and Pyrano[3,4-c]pyridines","volume":"56","author":"Sirakanyan","year":"2020","journal-title":"Russ. J. Org. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/jhet.5570150530","article-title":"New polyheterocyclic series based on 4,5,6,7-tetrahydrothieno[2,3-c]-pyridine","volume":"15","author":"Lalezari","year":"1978","journal-title":"J. Heterocycl. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s10593-014-1496-1","article-title":"Prediction of the biological activity spectra of organic compounds using the PASS online web resource","volume":"50","author":"Filimonov","year":"2014","journal-title":"Chem. Heterocycl. Compd."},{"key":"ref_16","first-page":"216","article-title":"Computer-aided drug design: From discovery of novel pharmaceutical agents to systems pharmacology","volume":"14","author":"Poroikov","year":"2020","journal-title":"Biochem. Suppl. Ser. B Biomed. Chem."},{"key":"ref_17","first-page":"569","article-title":"Psychotropic and Neurotropic activity","volume":"Volume 58","author":"Vogel","year":"2008","journal-title":"Drug Discovery and Evalution: Pharmacological Assays"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0920-1211(88)90054-X","article-title":"Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations","volume":"2","author":"Loscher","year":"1988","journal-title":"Epilepsy Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Baraban, S.C. (2009). Animal models of neuropsychiatric deseases. Animal models of Epilepsy. Methods and Innovations, Humana Press.","DOI":"10.1007\/978-1-60327-263-6"},{"key":"ref_20","first-page":"454","article-title":"Pentylenetetrazol seizure activity in mice as influenced by route of administration, acute adrenalectomy and reserpine","volume":"129","author":"Little","year":"1960","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0920-1211(02)00073-6","article-title":"Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy","volume":"50","author":"Loscher","year":"2002","journal-title":"Epilepsy Res."},{"key":"ref_22","unstructured":"Lery, R.H., Dreyfuss, F.E., Mattson, R.M., Meddrum, B.S., and Pentry, J.K. (1989). Experimental Selection, Qualification and Evalution of Anticonvulsant, Antiepileptic Drugs, Raven Press. Available online: https:\/\/europepmc.org\/article\/med\/4007184."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jps.3030460119","article-title":"The pharmacological activity of a series of basic esters of mono- and dialkylmalonic acids","volume":"46","author":"Dunham","year":"1957","journal-title":"J. Am. Pharm. Assoc. Sci. Ed."},{"key":"ref_24","first-page":"99","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol. Exper. Ther."},{"key":"ref_25","unstructured":"Mironov, A.H. (2012). Manual for Preclinical Studies of Drugs, Medicine. (In Russian)."},{"key":"ref_26","unstructured":"Mashkovskii, M.D. (2006). Lekarstvennie Sredstva [Medicinal Products], Novaya Volna."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/jps.2600580730","article-title":"Comparison of Two Methods for Measuring Drug-Induced Neurotoxicity","volume":"58","author":"Sofia","year":"1969","journal-title":"J. Pharm. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0166-4328(01)00292-3","article-title":"Factors controlling measures of anxiety and responses to novelty in the mouse","volume":"125","author":"File","year":"2001","journal-title":"Behav. Brain Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0091-3057(86)90552-6","article-title":"Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat","volume":"24","author":"Pelow","year":"1985","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(78)90118-8","article-title":"Behavioural despair in rats: A new model sensitive to antidepressant treatments","volume":"47","author":"Porsolt","year":"1978","journal-title":"Eur. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00210-011-0636-8","article-title":"Effects of antiepileptic drugs on GABA release from rat and human neocortical synaptosomes","volume":"384","author":"Kammerer","year":"2011","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature13293","article-title":"Crystal structure of a human GABAA receptor","volume":"512","author":"Miller","year":"2014","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1128\/MMBR.64.2.354-411.2000","article-title":"A functional-phylogenetic classification system for transmembrane solute transporters","volume":"64","author":"Saier","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1211\/jpp.57.10.0011","article-title":"Design and synthesis of long-chain arylpiperazines with mixed affinity for serotonin transporter (SERT) and 5-HT1A receptor","volume":"57","author":"Perrone","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_36","first-page":"12","article-title":"Pharmacology of rapid-onset antidepressant treatment strategies","volume":"62","author":"Blier","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.1166777","article-title":"A competitive inhibitor traps LeuT in an open-to-out conformation","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1124\/mol.51.5.889","article-title":"Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptor","volume":"51","author":"Kuipers","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11443","DOI":"10.1021\/ja105108q","article-title":"Conserved Binding Mode of Human \u03b22 Adrenergic Receptor Inverse Agonists and Antagonist Revealed by X-ray Crystallography","volume":"132","author":"Wacker","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1568026615666150112113040","article-title":"Identification of high affinity bioactive Salbutamol conformer directed against mutated (Thr164Ile) beta 2 adrenergic receptor","volume":"15","author":"Bandaru","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_41","unstructured":"(Accelrys Discovery Studio\u00ae Visualizer 3.5.0.12158, 2021). Accelrys Discovery Studio\u00ae Visualizer 3.5.0.12158, (Copyright\u00a9 2005-12, Accelrys Software Inc.) BIOVIA, Dassault Syst\u00e8mes, (Discovery Studio 2021 Client)."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/jm000292e","article-title":"Prediction of Drug Absorption Using Multivariate Statistics","volume":"43","author":"Egan","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/cc9800071","article-title":"A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. A qualitative and quantitative characterization of known drug databases","volume":"1","author":"Ghose","year":"1999","journal-title":"J. Comb. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1021\/jm015507e","article-title":"Simple selection criteria for drug-like chemical matter","volume":"44","author":"Muegge","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: The rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/11\/3320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:47Z","timestamp":1760162987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/11\/3320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["molecules26113320"],"URL":"https:\/\/doi.org\/10.3390\/molecules26113320","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}